-
Mashup Score: 6A new weight loss drug could become the best-selling drug of all time. Who can afford it? - 1 year(s) ago
In 2023, the FDA will likely approve Eli Lilly’s diabetes drug tirzepatide for weight loss — but there’s little indication insurers will widely cover the medication.
Source: NBC NewsCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 43Tirzepatide: a new low for bodyweight and blood glucose - 1 year(s) ago
The normal incretin effect—an enhanced prandial insulin response—is mediated mostly by meal-stimulated release of the intestinal hormones GLP-1 and glucose-dependent insulinotropic peptide (GIP).1 Analogues of GLP-1 that act as GLP-1 receptor agonists are established glucose-lowering agents that potentiate insulin release and suppress glucagon in a glucose-dependent manner. GLP-1 receptor…
Categories: Healthcare Professionals, Latest HeadlinesTweet-
RT @TheLancetEndo: #Tirzepatide: a new low for #bodyweight and blood #glucose https://t.co/Mr5SldRSGp #T2D #obesity #IDF2022 https://t.co/z…
-
-
Mashup Score: 7Tirzepatide: a new low for bodyweight and blood glucose - 1 year(s) ago
The normal incretin effect—an enhanced prandial insulin response—is mediated mostly by meal-stimulated release of the intestinal hormones GLP-1 and glucose-dependent insulinotropic peptide (GIP).1 Analogues of GLP-1 that act as GLP-1 receptor agonists are established glucose-lowering agents that potentiate insulin release and suppress glucagon in a glucose-dependent manner. GLP-1 receptor…
Categories: Endocrinology, Latest HeadlinesTweet-
#Tirzepatide: a new low for #bodyweight and blood #glucose https://t.co/Mr5SldRSGp #T2D #obesity #IDF2022 https://t.co/zy7a2wDYMZ
-
-
Mashup Score: 2
Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine.
Categories: Endocrinology, Latest HeadlinesTweet-
In people with type 2 #diabetes and high #cardiovascular risk, #tirzepatide slowed the rate of #eGFR decline and reduced #UACR in clinically meaningful ways compared with insulin glargine https://t.co/rpdGCOhEiU #T2D
-
-
Mashup Score: 0
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist, administered by a weekly injection, approved in the USA for the treatment of type 2 diabetes. The robust phase 3 SURPASS programme is documenting relevant efficacy of tirzepatide in reducing HbA1c and promoting weight loss.
Categories: Endocrinology, Latest HeadlinesTweet-
Anna Solini comments on: #Tirzepatide and #kidney function: an intriguing and promising observation https://t.co/bqxi3MHJFK #T2D
-
-
Mashup Score: 0
Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine.
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #tirzepatide versus insulin glargine on #kidney outcomes in type 2 #diabetes in the #SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial https://t.co/rpdGCOic8s #T2D #CKD #renal
-
-
Mashup Score: 0
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist, administered by a weekly injection, approved in the USA for the treatment of type 2 diabetes. The robust phase 3 SURPASS programme is documenting relevant efficacy of tirzepatide in reducing HbA1c and promoting weight loss.
Categories: Endocrinology, Latest HeadlinesTweet-
Linked commentary by Anna Solini: #Tirzepatide and #kidney function: an intriguing and promising observation https://t.co/bqxi3MZkxi #T2D #CKD #renal
-
-
Mashup Score: 1
Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine.
Categories: Endocrinology, Latest HeadlinesTweet-
In the Current Issue: Effects of #tirzepatide versus insulin glargine on #kidney outcomes in type 2 #diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial https://t.co/rpdGCOhEiU #T2D #CKD #renal
-
-
Mashup Score: 0
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist, administered by a weekly injection, approved in the USA for the treatment of type 2 diabetes. The robust phase 3 SURPASS programme is documenting relevant efficacy of tirzepatide in reducing HbA1c and promoting weight loss.
Categories: Endocrinology, Latest HeadlinesTweet-
Also read the Linked Comment by Anna Solini: #Tirzepatide and #kidney function: an intriguing and promising observation https://t.co/bqxi3MHJFK #T2D #CKD #renal
-
-
Mashup Score: 0
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist, administered by a weekly injection, approved in the USA for the treatment of type 2 diabetes. The robust phase 3 SURPASS programme is documenting relevant efficacy of tirzepatide in reducing HbA1c and promoting weight loss.
Categories: Endocrinology, Latest HeadlinesTweet-
Also read the Linked Comment by Anna Solini: #Tirzepatide and #kidney function: an intriguing and promising observation https://t.co/bqxi3MIhvi #T2D #CKD #renal
-
A new weight loss drug could become the best-selling drug of all time. In 2023, the FDA will likely approve the diabetes drug #tirzepatide for weight loss — but there's little indication insurers will widely cover the medication. Tragic & shortsighted https://t.co/t8Z1A8SckK